The below-mentioned stocks have made steady progress in achieving their organizational objectives which is why they are currently under the radar of investors. Let us now have a quick look on it:
Imugene Limited (ASX: IMU)
A clinical stage immuno-oncology company Imugene Limited’s (ASX: IMU) stock tumbled 5.0% on October 18, 2018 depicting a fall continued despite the release of positive outcomes from the Phase 1b study of its HER-Vaxx gastric cancer vaccine in patients expressing the HER2 target protein on 17 December 2018. As per the release, the company tested 14 patient study on three dose levels of HER-Vaxx in the combination of care chemotherapy, cisplatin, and fluorouracil or capecitabine. The study reported no safety issues, and HER-Vaxx was found to be well tolerated. Based on the safety and immunogenicity data, the study Cohort Review Committee has recommended a dose of 50 micrograms for the Phase 2 study which will test the efficacy, safety and immune response in 68 gastric cancer patients. Earlier in the month of November 2018, the company received a tax refund of $1.85 million as part of the Australian government’s R&D tax incentive which will further support the company’s commercial and clinical milestones. In the last six months, the share price of Imugene Limited decreased by 23.08 percent as on 17 December 2018. IMU’s shares traded at $0.019 with the market capitalization of circa $72.2 million as on 18 December 2018 (AEST 1:41 PM).
Biotron Limited (ASX: BIT)
Biotron Limited (ASX: BIT) is a clinical-stage Biotechnology Company in Australia which is focused on treating a number of serious viral diseases. The company is very much focused on designing and developing of a new class of antiviral drugs targeting viral? encoded viroporin proteins. Recently, the company exercised around $77 million BITOA options to raise approximately ~$4.707 million. This injection of the fund has placed Biotron in a sound financial position as it focuses on achieving a commercial outcome following the recent successful results from the phase 2 clinical trial of the company’s lead drug BIT225 for the treatment of HIV-1. Earlier in the month of October 2018, the company received a tax refund of $1.07 million. In the last six months, the share price of Biotron increased substantially by 576.47 percent as on 17 December. BIT’s shares traded at $0.115 with the market capitalization of circa $62.83 million as on 18 December 2018 (AEST 1:54 PM).
Volpara Health Technologies Limited (ASX: VHT)
Volpara Health Technologies Limited (ASX: VHT) is a digital health company which was having 99 VolparaEnterprise SaaS customers at the end of the 1H FY19. In H1 FY 2019, the company recorded an Annual Recurring Revenue (ARR) of $4.8 million and total contract value (TCV) of $6.5 million. In 1H19, the company increased its presence in Asia, especially Japan, where the company currently has 16 contracts. For the full year of FY 2019, the company is expecting ARR to be around $9 million. Over the period of last six months, the share price of Volpara Health Technologies increased by 40.51 percent as on 17 December 2018. VHT’s shares traded at $1.065 with the market capitalization of circa $198.89 million as on 18 December 2018 (AEST 1:57 PM).
Argosy Minerals Limited (ASX: AGY)
Argosy Minerals Limited (ASX: AGY) is a lithium production company which is having 77.5 percent interest in the Rincon Lithium Project in Salta Province, Argentina. Recently, the company announced further development at its Rincon Lithium Project where the next stage of evaporation pond construction works has been completed. The company has finished the construction of a combined total of around 38 hectares of lithium brine evaporation ponds, which are operational and providing concentrated lithium brine for use in the Company’s operating Stage 1 industrial-scale pilot plant. Meanwhile, the share price of AGY decreased by 38.46 percent in the last six months as on 17 December 2018. The company’s shares traded at $0.150 (-6.25 percent intraday) with the market capitalization of circa $147.76 million as on 18 December 2018 (AEST 1:59 PM).
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.